By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NeuroSigma, Inc. 

10960 Wilshire Boulevard
Suite 1230
Los Angeles  California  90024  U.S.A.
Phone: 310-479-3100 Fax: n/a


Medical Device

Company News
Preliminary Results Utilizing NeuroSigma's Monarch eTNS System For The Treatment Of Traumatic Brain Injury Presented At The North American Neuromodulation Society Annual Meeting 12/10/2015 6:54:35 AM
NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD 11/16/2015 8:39:38 AM
NeuroSigma Withdraws $50 Million IPO Plans 9/29/2015 6:43:09 AM
FDA Grants Faustus Forschungs Cie. Translational Cancer Resea Humanitarian Use Device (HUD) Designation 1/6/2015 10:52:56 AM
University of California, Los Angeles (UCLA) Launches Phase 2 Pediatric Clinical Trial For The Treatment Of ADHD With NeuroSigma, Inc.'s eTNS System 1/5/2015 7:08:58 AM
NeuroSigma, Inc. Congratulates Brazilian Medical Team For Their Top-Line Results In Phase 2 Clinical Trial Of Etns For Treatment Of Depression 11/19/2014 12:03:44 PM
NeuroSigma, Inc. Announces Top-Line Findings Of University of California, Los Angeles (UCLA) Phase 2 Clinical Trial Of eTNS For The Treatment Of Depression 11/17/2014 10:13:00 AM
NeuroSigma, Inc. Receives Notice Of Allowance From The Mexican Institute Of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 11/3/2014 8:21:29 AM
NeuroSigma, Inc. Receives Notice of Allowance Of U.S. Patent Application 10/21/2014 8:10:07 AM
NeuroSigma, Inc. And The U.S. Veterans Administration (VA) Enter Into Cooperative Research And Development Agreement (CRADA) 10/15/2014 8:28:43 AM